- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02439593
Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study (HEATPAC)
A Phase II Randomized Study of Concurrent Hyperthermia and Chemoradiotherapy vs. Chemoradiotherapy Alone Following Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (HEATPAC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This phase II randomized trial is a part of the comprehensive protocol designed for the locally advanced pancreatic cancers (LAPC). All patients of LAPC, fulfilling the following criteria of "Unresectable LAPC" would be considered to be eligible for enrolment in the study.
These include:
- Major venous infiltration / thrombosis of the portal vein or superior mesenteric vein extending for several centimeters (precluding vein resection and reconstruction)
- Tumor encasement (≥180°) of the superior mesentric artery or proximal hepatic artery
- Tumor abutment (<180°) of the celiac trunk
- Tumor invasion of the aorta
- Presence of metastasis to lymph nodes beyond the field of resection All patients would be reviewed at the Pancreas Cancer Tumor Board, University Hospital Zurich and those fulfilling the above condition/s would be considered for the study protocol of LAPC. Following a detailed work up, all eligible patients with primary tumours more than 4 cm would be considered for HEATPAC study.
Patients would be randomized by random digit using a double blinded strategy into either (a) Control group : Treated with concurrent chemoradiotherapy or (b) Study group: Treated with local hyperthermia along with concurrent chemoradiotherapy.
Treatment in both groups would be initiated with 4 cycles of neo-adjuvant chemotherapy (FOLFIRINOX). At completion of 4 cycles of neo-adjuvant FOLFIRINIOX, patients would be evaluated by PET-CT, 3-4 week following the last cycle of FOLFIRINIOX. Patients in control group would be taken up for concurrent gemcitabine (400 mg / sq.m weekly) along with loco-regional radiotherapy by SIB-IMRT to a dose of 50.4 Gy in 28 fractions. Patients in the study group would be receiving loco-regional hyperthermia to a temperature of 40-41°C, weekly for 1 hour before gemcitabine and before radiotherapy. The gemcitabine and in loco-regional radiotherapy in study group would be similar to that of the control group.
Following the completion of this treatment, patients of both groups would be considered for 8 cycles of adjuvant FOLFIRINOX and followed up with both clinical, heamatological and imaging studies as detailed in the study protocol.
Primary endpoint:
- Overall survival at 1 year
- To assess the acute and the late morbidities associated with hyperthermia and chemoradiotherapy in concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone.
Secondary endpoints:
- To compare the disease free survival in patients of locally advanced pancreatic cancers following neoadjuvant chemotherapy with FOLOFIRINOX treated with hyperthermia and chemoradiotherapy versus chemoradiotherapy alone.
- To assess the patterns of failure (both local and systemic) in patients of both treatment arms.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Niloy R Datta, MD,DNB
- Phone Number: +41628422088
- Email: niloyranjan.datta@ksa.ch
Study Contact Backup
- Name: Stephan Bodis, MD
- Phone Number: +41628385371
- Email: stephan.bodis@ksa.ch
Study Locations
-
-
Aargau
-
Aarau, Aargau, Switzerland, CH 5001
- Recruiting
- Kantonsspital Aarau
-
Contact:
- Niloy R Datta, MD, DNB
- Phone Number: 0041 62 8389559
- Email: niloyranjan.datta@ksa.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients of locally advanced pancreatic cancer with
- Major venous infiltration / thrombosis of the portal vein or superior mesenteric vein extending for several centimeters
- Tumor encasement (≥180°) of the superior mesentric artery or proximal hepatic artery
- Tumor abutment (<180°) of the celiac trunk
- Tumor invasion of the aorta
- Presence of metastasis to lymph nodes beyond the field of resection
- Histopathologically proven ductal adenocarcinoma of the pancreas (biopsy /cytology)
- Eastern Cooperative Oncology Group (ECOG) performance scale 0 and 1
- Age: 18 to 80 years
- At least one of the diameters of the primary tumor or regional lymph node or both should be greater than 4 cm, as confirmed on contrast-enhanced computed tomography (CECT).
- Patients, have primary tumor or regional lymph node or both lesser than 4 cm, as confirmed on CECT but have specific medical contraindications to stereotactic body radiation therapy or irreversible electroporation or as per patient's preference could be considered for HEATPAC.
- No evidence of any distant metastasis
- Patients with microscopic peritoneal carcinomatosis, detected on laparoscopy following 4 cycles on neo-adjuvant FOLFIRINOX would be included.
- Estimated life expectancy of at least 6 months
- Adequate kidney functionality defined as creatinine clearance >50ml/min
- Adequate liver functionality defined as total bilirubin ≤ 2x of the upper limit of normal
- Adequate bone marrow reserves: White blood cell count ≥ 2.5 x 10˄9/L, Platelet count ≥ 100 x 10˄9/L, Hemoglobin ≥ 8.0g/L
- Women of child-bearing age must secure sufficient contraception control during the clinical trial and six months after the clinical trial is completed
- For females of child bearing potential, negative pregnancy test within 2 week prior to randomization.
- Female patients should not be lactating
- Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
Exclusion Criteria:
- Histopathology other than ductal adenocarcinoma pancreas
- Prior radiotherapy to the site of treatment
- Patients with unequivocal distant metastasis including liver
- Patients with gross peritoneal carcinomatosis on laparoscopy
- No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin
- No serious medical illness which would prevent informed consent or limit survival to less than 2 years
- Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
- Psychiatric or addictive disorders or other conditions that would preclude the patient from meeting the study requirements.
- Patients having metal implants, pacemakers or clustered markers.
- Metallic endobiliary stenting would be a contraindication, hence plastic stents may be used if biliary drainage is indicated.
- Patient with a history of myocardial infarction within the past 12 months
- No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
- Pre-existing grade 2 peripheral neuropathy
- Any known contraindication or hypersensitivity to the chemotherapeutic agents
- Pregnancy, lactation period or lack of reliable contraception
- Any other disease or therapy, which, present a risk to the patient or which are not compatible with the aims of the clinical trial
- Patients would express their inability to travel on their own to Kantonsspital Aarau, (KSA) for hyperthermia treatment
- Indications that the person concerned will be noncompliant to the clinical trial plan because of unwillingness to cooperate or difficulties in keeping the check-up appointments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Chemoradiotherapy (CTRT) (Control Group)
Intervention type: Drug and Radiation Intervention name: Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Intervention description: Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 |
CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
|
Experimental: Thermochemoradiotherapy (CTRTHT)
Intervention type: Drug, Radiation and Hyperthermia Intervention name: Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia), Intervention description: Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week |
Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (at 1 year)
Time Frame: From date of randomization until the date of death from any cause assesed at 1 year or whichever is earlier
|
Overall survival
|
From date of randomization until the date of death from any cause assesed at 1 year or whichever is earlier
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (as per Response Evaluation Criteria in Solid Tumours (RECIST), v1.1)
Time Frame: From date of randomization until the first docemented disease progression as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks
|
Progression free survival
|
From date of randomization until the first docemented disease progression as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks
|
Patterns of failure : both local and systemic (as per RECIST, v1.1)
Time Frame: From date of randomization until the disease progression either locally or at distant sites as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks
|
Patterns of failure : both local and systemic
|
From date of randomization until the disease progression either locally or at distant sites as evident on CECT / PET-CT / MRI as per RECIST criteria (v1.1), whichever came first assessed upto the end of study period of 60 weeks
|
Acute and late morbidity (as per Common Toxicity Criteria for Adverse Effects (CTCAE) v4.03)
Time Frame: Acute or late morbidity from date of randomization until the patients death from any cause as per the CTCAE v4.03 whichever came first assessed upto the end of study period of 60 weeks
|
Acute and late morbidity that are ascribed to treatment
|
Acute or late morbidity from date of randomization until the patients death from any cause as per the CTCAE v4.03 whichever came first assessed upto the end of study period of 60 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Niloy R Datta, MD,DNB, Kantonsspital Aarau
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEATPAC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Pancreas
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Joseph J. CullenNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaboratorsActive, not recruitingAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); BioMed Valley Discoveries, IncTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
BioXcel Therapeutics IncIQVIA BiotechWithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Baylor Research InstituteUnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas CancerUnited States
-
AmgenTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
Washington University School of MedicineTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Newcastle-upon-Tyne Hospitals NHS TrustMedtronicCompletedPancreas Adenocarcinoma | Chronic Pancreatitis | Pancreas Cancer | Pancreas Neoplasm, BenignUnited Kingdom
Clinical Trials on Chemoradiotherapy (CTRT)
-
Mansoura UniversityCompletedRectal Cancer | Bowel; Functional SyndromeEgypt
-
Institut du Cancer de Montpellier - Val d'AurelleCompleted
-
Cancer Institute and Hospital, Chinese Academy...Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; West China... and other collaboratorsUnknownLung Neoplasms | Carcinoma, Small CellChina
-
Albert Einstein College of MedicineActive, not recruitingNon-small Cell Lung CancerUnited States
-
Kyungpook National University HospitalRecruiting
-
Beijing Chao Yang HospitalRecruitingLocal Recurrence of Malignant Tumor of Rectum | Circumferential Resection Margin | Intraoperative Perforation of Rectum | Disease-free Survival | Overal SurvivalChina
-
Guizhou Provincial People's HospitalRecruiting
-
China Medical University HospitalUnknownChemoradiation | Rectal CancerTaiwan
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedNon Small Cell Lung CancerChina